...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: BIO CEO Slides Up
1
Feb 12, 2019 02:14PM
2
Feb 12, 2019 02:23PM
1
Feb 12, 2019 02:28PM
8
Feb 13, 2019 10:21AM
2
Feb 13, 2019 10:36AM
1
Feb 13, 2019 11:36AM
1
Feb 13, 2019 12:00PM
3
Feb 13, 2019 12:06PM

Feb 13, 2019 12:11PM

hummm,,,I am not sure about the suggestion here that this management team cant manage some relatively simple math around enrollment, events, time overall, adjudication and the tally!,,,when we have access to computerized data analysis for end of trial,,,, so if they can figure out the slant on epigenetics and the MOA of their 208 molecule I think it is an embarrassment to think they have limited understanding around the probable event target numbers and timing in BoM.

It is more reasonable to assume these adjudicated event numbers are delayed by simply the unexpected lack of events which plays into the meet and exceed side of the RRR%,,,cuz the placebo group should have been very easily given an approximate event number based on the design data driving this trial!! If that is untrue then the trial design created by this management team is nothing more and should be understood to be amateur at best. jmo

2
Feb 13, 2019 01:02PM
3
Feb 13, 2019 01:18PM
2
Feb 13, 2019 02:10PM
2
Feb 13, 2019 04:40PM
3
Feb 13, 2019 05:10PM
4
Feb 13, 2019 06:51PM
3
Sep 18, 2019 03:54PM
5
Sep 18, 2019 04:37PM
5
Sep 18, 2019 05:21PM
3
Sep 18, 2019 06:11PM
4
Sep 18, 2019 06:31PM
2
Sep 18, 2019 07:00PM
4
Sep 18, 2019 09:04PM
7
Sep 18, 2019 09:29PM
1
Sep 18, 2019 09:38PM
5
Sep 18, 2019 10:26PM
3
Sep 18, 2019 11:02PM
10
Sep 19, 2019 05:07AM
1
Sep 19, 2019 08:52AM
1
Sep 19, 2019 09:46AM
4
Sep 19, 2019 09:48AM
3
Sep 19, 2019 09:57AM
4
Sep 19, 2019 11:01AM
6
Sep 19, 2019 08:25PM
7
Sep 19, 2019 08:33PM
Share
New Message
Please login to post a reply